Factors associated with drug-free remission at 5 year in early onset axial spondyloarthritis patients: data from the DESIR cohort.
Sign Up to like & getrecommendations! Published in 2022 at "Joint bone spine"
DOI: 10.1016/j.jbspin.2022.105358
Abstract: OBJECTIVES To assess the frequency of patients in drug-free remission at 5 years in a cohort of early axial SpA, and the factors associated with this remission. METHODS Patients: Patients included in the DESIR (DEvenir… read more here.
Keywords: year visit; free remission; drug free; remission ... See more keywords
Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106578
Abstract: BACKGROUND Molecular response (MR) 4.0 or 4.3 remains an indicator of treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) in countries that accept it as the criterion of undetectable minimal residual disease (UMRD)… read more here.
Keywords: treatment free; treatment; mr4; free remission ... See more keywords
Rheumatoid arthritis: Moving towards IMPROVED drug-free remission
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Rheumatology"
DOI: 10.1038/nrrheum.2018.49
Abstract: The newly published 5-year outcomes of the IMPROVED trial demonstrate the feasibility of achieving long-term drug-free remission in early rheumatoid arthritis (RA). These findings raise the bar and support the use of a remission induction… read more here.
Keywords: free remission; remission; rheumatoid arthritis; drug free ... See more keywords
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0867-0
Abstract: In CML, treatment-free remission (TFR) refers to having a stable deep molecular response without the need for ongoing tyrosine kinase inhibitor treatment. Whilst recommendations exist about the technical management of stopping and re-starting therapy, much… read more here.
Keywords: treatment free; areas unmet; treatment; patient perspective ... See more keywords
Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2023.2157814
Abstract: ABSTRACT Introduction Drug-free remission (DFR) and its maintenance have been defined as the most desirable outcome for rheumatoid arthritis (RA) patients. DFR is linked to resolution of arthritis-related symptoms and restoration of normal functioning. However,… read more here.
Keywords: remission; rheumatoid arthritis; free remission; drug free ... See more keywords
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2018296
Abstract: ABSTRACT Introduction In chronic myeloid leukemia (CML) patients who have reached a deep and sustained reduction of residual disease can attempt a discontinuation. The ‘treatment-free remission’ (TFR) has become a real long-term endpoint for 30–40%… read more here.
Keywords: myeloid leukemia; free remission; treatment free; chronic myeloid ... See more keywords
High Long-Term Drug-Free Remission Rate for Acute Vogt-Koyanagi-Harada Disease with Appropriate Immunosuppressive Regimen.
Sign Up to like & getrecommendations! Published in 2023 at "Retina"
DOI: 10.1097/iae.0000000000003837
Abstract: PURPOSE To report the clinical profile and outcomes of acute Vogt-Koyanagi-Harada (VKH) disease with a strict immunosuppression regimen and investigate the risk factors for a prolonged disease course. METHODS A total of 101 patients with… read more here.
Keywords: long term; term drug; free remission; drug free ... See more keywords
Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Pediatric Gastroenterology and Nutrition"
DOI: 10.1097/mpg.0000000000003291
Abstract: Supplemental Digital Content is available in the text ABSTRACT Introduction: While fecal calprotectin (FC) is used to assess disease activity in ulcerative colitis (UC) there are little data concerning the role of serial FC levels… read more here.
Keywords: fecal calprotectin; change; year; week ... See more keywords
OP0240 Favourable longterm outcome in patients with giant cell arteritis treated with tocilizumab. real life data from a swiss centre
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6585
Abstract: Background Tocilizumab (TCZ) has been shown to be effective for achieving sustained glucocorticoid (GC)-free remission in patients with giant cell arteritis (GCA) 1,2. However, data on real life patients and longterm follow up is still… read more here.
Keywords: giant cell; treatment; tcz; remission ... See more keywords
FRI0124 FACTORS ASSOCIATED WITH PERSISTENT DRUG-FREE REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.5677
Abstract: Background: Persistent drug-free remission of RA is a condition that is close to “cure” of the disease. However, long-term drug-free remission is considered to be rare and very challenging to reach. Also, little data are… read more here.
Keywords: none declared; persistent drug; free remission; remission ... See more keywords
Abstract 2181: Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2181
Abstract: Introduction: ALK-positive ALCL accounts for 0.8% of Korean lymphoma patients. ALK TKIs are effective and durable, but clinical outcomes after treatment discontinuation are unknown. We analyzed outcomes and minimal residual disease (MRD) in adult ALK-positive… read more here.
Keywords: treatment free; free remission; alk positive; alk ... See more keywords